We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.


AgPlus Diagnostics

Status: Expired

Nov 1st 2019 - May 30th 2020

AgPlus has created a diagnostic platform for detecting human diseases and delivering laboratory instrument results instantly, whilst keeping in mind the business requirements and unmet requirements. The company works in collaboration with leading diagnostics companies to improve and share products quickly and globally. It aims is to become known as a leader in Point of Care diagnosis.

read more read less


Log in to comment

Funding progress

More from Medical

Span Health is a digital care platform that aims to help people avoid lifestyle-induced diseases, symptoms, medication, and complications. The company has helped more than 10,000 people to live a better and longer life. Span Health's easy-to-use mobile application allows patients to chat with clinicians, order blood tests at home, book video consultations, and see results in the application itself. Moreover, in 2019, the company agreed on a National Health Service (NHS) pilot test for 100 patients in collaboration with the National Institute of Health Research in North West London. Span Health will use the investment to provide employees with blood tests to screen for health risk factors and recover from detected illness safely and sustainably, improve its platform data insights, prediction and machine learning to better structure the clinician's processes, and further reduce its operational costs.
pledged: 113% days to go: 30 investment: £113,417
Tourniglo is a company that has come up with a unique two in one emergency tourniquet with a built-in torch. The innovation was driven by an identified need within the emergency services to provide an immediately available light source in dim-lighted areas when undertaking a patient or casualty eye examination as well as for military and close protection staff who might need to inject intravenous medication in rural areas. The global tourniquet systems market is expected to reach half a billion US dollars by 2025. The company aims to launch the production of its first product. Additionally, Tourniglo has been featured on the BBC website and has won various medals at international events, including a 'Gold Medal' at the World Invention Awards. The company requires investment to set-up manufacturing, packaging and distribution, and grow sales for the first year of commercialisation.
pledged: 29% days to go: 10 investment: £26,487
Imagen is a company that has developed an automated, sophisticated algorithmic technique, PredictRx, to find the right treatment for any cancer type. Imagen collects the cancer samples from a patient, grows it in its specialised growth medium, and then subjects the medium to an automated fluorescence microscopy screening to measure drug responses on live tumour cells. The company's AI-powered biobank of over 150,000 drug responses then gives the best possible cancer treatment options, allowing the company to expand in the pharmaceutical sector by satisfying its unmet demand for patient-derived cancer models. Imgen requires investment to scale its infrastructure to create the world's leading 'Biobank' of clinically relevant patient-derived cancer models whilst building the most comprehensive big data set available in cancer research.

Pitch Rated



rating powered by


pledged: 134% days to go: 7 investment: £805,967
Accunea is the world’s first real-time continuous organ function monitoring company, specializing in biomarkers for kidney transplantation. Targeting NHS hospitals in the UK undertaking renal transplantation, the company aims to provide relief to patients awaiting organ transplants by ensuring availability of more organs for transplant and reducing the numbers of deaths due to increasing waiting list times. For this purpose, the company has designed a miniature analysis device which constantly monitors markers of kidney function and metabolism through a standard dribble line put into the vein of a patient. Accunea is raising £400,000 at a pre-money valuation of £2,230,000. The funds will be used to achieve clinical utility in Kidney and Pancreas.

Pitch Rated



rating powered by


pledged: 97% days to go: 24 investment: £388,038
A medical condition management platform allowing clinicians to create their own app to improve a patient's health whilst reducing costs. Living With develops smart apps specific to a person's condition, they currently have 3 products with another in the development stage. Their primary app, Squeezy, is the top paid medical app in the UK that helps patients with their pelvic floor exercises. Other apps, allow clinicians to monitor a patient's bowel and bladder health, as well as those with rheumatoid arthritis. These apps are already in use at multiple NHS Trusts and clinics. Funds are being raised to complete development of their apps to help those with lupus and lung cancer, in addition to further developing their existing products. The company aims to have thousands of apps that will be available worldwide to provide self-service treatment at any time. Living With is expecting to earn £1.07m in revenue by the end of March 2019.
pledged: 81% days to go: 22 investment: £250,000

  • £65,004
  • 4%
    of goal


    pre-money valuation


    pledge per investor

    company number

    company status

    incorporated 5 years

  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph